0000000000954127

AUTHOR

Jelena Rosentreter

0000-0001-7802-9135

showing 2 related works from this author

Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitor…

2020

Introduction Cancer patients tend to prefer oral instead of parenteral chemotherapy. To date, there is little evidence on the medication adherence in cancer patients. We investigated medication adherence to tyrosine kinase inhibitors in patients suffering from non-small cell lung cancer. Methods Tyrosine kinase inhibitor adherence was measured electronically by MEMS® (medication event monitoring system) over at least six months. Adherence rates were calculated in terms of Dosing Compliance, Timing Compliance, Taking Compliance, and Drug Holidays. Patients were dichotomized as adherent when Dosing Compliance and Timing Compliance were ≥80%, Taking Compliance ranged between 90 and 110%, and &…

OncologyAdultMalemedicine.medical_specialtyLung Neoplasmsmedicine.drug_classmedicine.medical_treatmentTyrosine-kinase inhibitorMedication Adherence03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineCarcinoma Non-Small-Cell LungmedicineHumansPharmacology (medical)ddc:610030212 general & internal medicinePatient Reported Outcome MeasuresProspective StudiesLung cancerAdverse effectProtein Kinase InhibitorsAgedAged 80 and overChemotherapybusiness.industryCancerMiddle AgedProtein-Tyrosine Kinasesmedicine.diseaseOncology030220 oncology & carcinogenesisQuality of LifeObservational studyFemalebusinessTyrosine kinaseJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct

Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an…

2020

Introduction Pharmacokinetic interaction of high-dose methotrexate (MTX) and other concomitantly administered renally secreted medicinal products may lead to insufficient methotrexate serum level decrease and significant MTX toxicity. Case report We report the case of an 18-year-old male patient treated with high-dose MTX for an osteosarcoma and with high-dose piperacillin-tazobactam at the same time. MTX serum levels were severely elevated 24 hours after the MTX infusion and did not decrease in accordance with the specific calcium folinate rescue protocol. The patient experienced renal failure accompanied by neurological symptoms, most consistent with MTX-related renal and CNS toxicity. Ma…

musculoskeletal diseasesMaleAntimetabolites AntineoplasticAdolescentBone Neoplasms030204 cardiovascular system & hematologyPharmacology03 medical and health sciences0302 clinical medicinemedicineHumansPharmacology (medical)Drug InteractionsRenal InsufficiencyPiperacillinOsteosarcomabusiness.industryNeurotoxicitymedicine.diseaseHigh dose methotrexateAnti-Bacterial AgentsMethotrexateOncology030220 oncology & carcinogenesisPiperacillin/tazobactamOsteosarcomaMethotrexateNeurotoxicity SyndromesbusinessPharmacokinetic interactionmedicine.drugJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct